BiliPredics
Improving Clinical Decision Making
for Newborn Jaundice
The BiliPredics, formerly NeoPrediX B.1, transforms clinical data into scientifically validated predictions to help clinicians make faster, more accurate decisions in the care of newborns at risk of jaundice.
Personalize and Optimize Newborn Care with BiliPredics
- BiliPredics accurately identifies at-risk newborns, improving discharge planning and reducing unnecessary treatments, tests, and extended hospital stays. This ensures safer transitions home and optimizes hospital resources.
- Using a validated algorithm from multi-site clinical trials, BiliPredics standardizes jaundice management with reliable, evidence-based insights tailored to individual patients.
- Its automated, precise bilirubin forecasting streamlines workflows, reduces clinician workload, and allows healthcare providers to focus more on direct patient care, improving overall quality and efficiency.
ADVANTAGES
Key Features of BiliPredics
- Scientifically validated 60-hour dynamic bilirubin forecasts for precision care.
- Intuitive web application with clear visualizations of bilirubin trends and treatment thresholds.
- Adheres to the latest AAP 2022 guidelines for managing hyperbilirubinemia, ensuring up-to-date best practices.
- Displays relevant historical patient data to support informed trend analysis, aiding in more effective decision-making.
- Generates comprehensive PDF reports to support seamless communication and continuity of care between providers and families.
- Full integration with EMR systems or availability as a stand-alone application, improving workflow adaptability.
The NeoPredics BiliPredics web application
Transforming Jaundice Care in the Newborn Nursery
BiliPredics is designed for:
Healthcare Professionals
Streamline decision-making with accurate, timely forecasts that reduce unnecessary interventions and improve patient safety.
Supervisors and Administrators
Enhance patient outcomes, optimize resource allocation, and boost operational efficiency by identifying which newborns truly need extended care.
IT / Operations
Benefit from easy integration, user-friendly design, and a system that fits seamlessly into existing workflows.
3.5M+
births per year
in the USA
6 OUT
OF 10
babies develop
jaundice
1 OUT
OF 10
newborns require
phototherapy
2 OUT
OF 5
newborns move into
a higher risk zone
after discharge
VALIDATION
Clinical Validation
Our solution is validated by a multi-site clinical study, incorporating risk factors and patient diagnoses. The algorithm is powered by data from 15,000 newborns, providing accurate predictions that support better discharge care planning and reduce hospital readmissions.
Contact Us
Learn more about how BiliPredics can improve care at your institution.
Email us at
NeoPredics AG (Switzerland)
Aeschengraben 20, 4051 Basel, Switzerland
Executive Team: Jörg Schmidt, Prof. Dr. Marc Pfister , Prof. Dr. Sven Wellmann
Registered office: Basel
Commercial register number CH-270.3.016.001-3
Chairman of the board: Dr. Gerhard Ries
NeoPredics USA, Inc. (US)
110 E Broward Blvd #1700
Fort Lauderdale, FL 33301, United States
Phone: +1 (954)-315-3884
NeoPredics AG (Germany)
Franz-Mayer-Straße 1, 93053 Regensburg
Excecutive Board: Thorsten Waloschek (chairman), Jörg Schmidt
Registered Office: Regensburg
Commercial register number: HRB 18679
Supervisory Board: Dr. Volker Pfahlert (chairman), Arne Kirchner, Prof. Dr. Marc Pfister, Dr. Gerhard Ries, Prof. Dr. Sven Wellmann
